{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:47:13Z","timestamp":1767894433988,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,3,21]],"date-time":"2006-03-21T00:00:00Z","timestamp":1142899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1186\/1471-2407-6-76","type":"journal-article","created":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T13:30:18Z","timestamp":1144330218000},"source":"Crossref","is-referenced-by-count":8,"title":["Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience"],"prefix":"10.1186","volume":"6","author":[{"given":"Alessandro","family":"Passardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Massa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wainer","family":"Zoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Milandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Zumaglini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Maltoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Luca","family":"Frassineti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dino","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,3,21]]},"reference":[{"key":"428_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/sj.bjc.6602680","volume":"93","author":"D Ghersi","year":"2005","unstructured":"Ghersi D, Wilcken N, Simes RJ: A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer. 2005, 93: 293-301. 10.1038\/sj.bjc.6602680.","journal-title":"Br J Cancer"},{"key":"428_CR2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/cncr.20757","volume":"103","author":"E Bria","year":"2005","unstructured":"Bria E, Giannarelli D, Felici A, Peters WP, Nistico C, Vanni B, Cuppone F, Cognetti F, Terzoli E: Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Pooled analysis of 2805 patients. Cancer. 2005, 103: 672-679. 10.1002\/cncr.20757.","journal-title":"Cancer"},{"key":"428_CR3","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1200\/JCO.2001.19.6.1707","volume":"19","author":"J Jassem","year":"2001","unstructured":"Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C, Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001, 19: 1707-1715.","journal-title":"J Clin Oncol"},{"key":"428_CR4","first-page":"137a","volume":"21","author":"JR Mackey","year":"2002","unstructured":"Mackey JR, Paterson A, Dirix LY, Chap L, Dewar J, Martin M, Chan S, Tang S-C, Dugan W, Gil M, Zaluski J, Russel C, Vogel C, Efremedis A, Appia F, Brunel E, Hatteville L, Azli N, Nabholtz J-M, Cross Cancer Inst, Edmonton, AB, Canada; Tom Baker Cancer Centre, Calgary, AB, Canada; Med. Instituut St Augustin, Oosterveldlaan, Belgium; Sir Charles Gairdner Hospital, Nedlands, Australia; UCLA School of Medicine Los Angeles, CA; Hospital Clinico San Carlos, Madrid, Spain; City Hospital, Nottingham, UK; Dr. H. Bliss Murphy Centre, Newfoundland, Canada; Indianapolis Community Care Center, Indianapolis, IN; Hospital Duran i Reynals, Barcelona, Spain; GreatPoland Oncology Center, Poznan, Poland; University of Southern California, Los Angeles, CA; Southpoint Medical Center, Plantation, FL; St. Savas Oncology Hospital, Athens, Greece; Aventis Pharma, Antony, France; Ascopharm, Paris, France: Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol. 2002, 21: 137a-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"428_CR5","first-page":"280a","volume":"19","author":"H Luck","year":"2000","unstructured":"Luck H, Thomssen C, Untch M, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Moebus V, Steinfeld D, Bauknecht T, Schroeder W, Jackisch C: Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC): epirubicin\/paclitaxel (ET) vs. epirubicin\/cyclophosphamide (EC). A study of the AGO Breast Cancer Group [abstract]. Proc Am Soc Clin Oncol. 2000, 19: 280a-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"428_CR6","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1200\/JCO.2002.11.005","volume":"20","author":"L Biganzoli","year":"2002","unstructured":"Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase IIII Trial. J Clin Oncol. 2002, 20: 3114-3121. 10.1200\/JCO.2002.11.005.","journal-title":"J Clin Oncol"},{"key":"428_CR7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","volume":"21","author":"JM Nabholtz","year":"2003","unstructured":"Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P, TAX 306 Study Group: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003, 21: 968-975. 10.1200\/JCO.2003.04.040.","journal-title":"J Clin Oncol"},{"key":"428_CR8","first-page":"84a","volume":"20","author":"J Carmichael","year":"2001","unstructured":"Carmichael J: UKCCCR trial of epirubicin and cyclophosphamide (EC) vs. Epirubicin and Taxol\u00ae (ET) in the first line treatment of women with metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol. 2001, 20: 84a-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"428_CR9","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.1200\/JCO.2005.06.236","volume":"23","author":"M Bontenbal","year":"2005","unstructured":"Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C: Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol. 2005, 23: 7081-7088. 10.1200\/JCO.2005.06.236.","journal-title":"J Clin Oncol"},{"key":"428_CR10","doi-asserted-by":"crossref","first-page":"510a","DOI":"10.1200\/jco.2004.22.14_suppl.510","volume":"22","author":"KS Albain","year":"2004","unstructured":"Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska A, Pawlicki M, Melemed AS, O'Shaughnessy J, Reyes JM: Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival [abstract]. Proc Am Soc Clin Oncol. 2004, 22: 510a-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"428_CR11","doi-asserted-by":"crossref","first-page":"581a","DOI":"10.1200\/jco.2005.23.16_suppl.581","volume":"23","author":"S Chan","year":"2005","unstructured":"Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Lluch A, Schneeweiss A, Llombart A, Carrasco E, Fumoleau P: Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients: results of a European phase III study. Proc Am Soc Clin Oncol. 2005, 23: 581a-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"428_CR12","unstructured":"Frassineti GL, Zoli W, Silvestro L, Serra P, Milandri C, Tienghi A, Gianni L, Gentile A, Salzano E, Amadori D: Paclitaxel plus doxorubicin in breast cancer: an Italian experience. Semin Oncol. 1997, 19-25. Suppl 17"},{"key":"428_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/(SICI)1097-0215(19990129)80:3<413::AID-IJC13>3.0.CO;2-I","volume":"80","author":"W Zoli","year":"1999","unstructured":"Zoli W, Ricotti L, Barzanti F, Dal Susino M, Frassineti GL, Milandri C, Casadei Giunchi D, Amadori D: Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer. 1999, 80: 413-416. 10.1002\/(SICI)1097-0215(19990129)80:3<413::AID-IJC13>3.0.CO;2-I.","journal-title":"Int J Cancer"},{"key":"428_CR14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1179\/joc.2003.15.5.488","volume":"15","author":"T Ibrahim","year":"2003","unstructured":"Ibrahim T, Fabbri M, Frassineti GL, Zoli W, Monti M, Ricotti L, Amadori D: Doxorubicin, paclitaxel and gemcitabine: a phase I study of a new sequential treatment in stage IIIB \u2013 IV breast cancer. J Chemother. 2003, 15: 488-494.","journal-title":"J Chemother"},{"key":"428_CR15","unstructured":"Zielinski CC: Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer. Oncology (Huntigt). 2003, 36-40. Suppl 14"},{"key":"428_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1011945623464","volume":"68","author":"PF Conte","year":"2001","unstructured":"Conte PF, Gennari A, Donati S, Salvadori B, Baldini E, Bengala C, Pazzagli I, Orlandini C, Danesi R, Fogli S, Del Tacca M: Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat. 2001, 68: 171-179. 10.1023\/A:1011945623464.","journal-title":"Breast Cancer Res Treat"},{"key":"428_CR17","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1200\/JCO.2005.12.106","volume":"23","author":"C Zielinski","year":"2005","unstructured":"Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T: Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol. 2005, 23: 1401-1408. 10.1200\/JCO.2005.12.106.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-6-76\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-76.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-76","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-76.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T15:16:34Z","timestamp":1586790994000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-6-76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,21]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-6-76","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,21]]},"article-number":"76"}}